Clover Health Investments Corporation (CLOV) 시세

Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
Robust plan benefits powered member growth, mainly driven by switchers from other plans
Company will focus on balancing profitability with strategic investments in growth and technology to take advantage of strong market opportunity
~95% of Clover’s January 1, 2025 membership is in its flagship 4 Star PPO plan
WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover’s flagship 4-Star PPO plan.

“Driven by robust plan benefits and our 4 Star rating, we’ve delivered exceptional member growth, and I feel honored to bring so many new people into our unique model of care,” said Andrew Toy, CEO of Clover Health. “We invest deeply in using technology to improve clinical outcomes through the earlier identification, management and treatment of chronic disease, a clear differentiator from our peers. Looking forward, we will take advantage of the strong market opportunity in front of us, by making strategic investments in growth as well as continuing to widen our AI-powered technology moat.”

Clover’s 4-Star rating PPO plan reflects the Company’s deep investment in care quality, with top performance across key HEDIS measures—an industry standard for healthcare quality. This achievement also positions Clover for an anticipated 5% benchmark increase in payment year 2026 (PY26), strengthening the company’s ability to reinvest in improving benefits and further accelerating membership growth.

Jamie Reynoso, CEO of Medicare Advantage at Clover Health, added: “Our foundational investments over the last few years—ranging from enhanced care management to operational efficiencies—are paying off. Keeping a keen focus on improving the health of our members, by being an active participant in their care management, Clover is in an incredibly strong position to continue this above-market growth trajectory while of course maintaining profitability. Our strong membership growth, coupled with the expected 2026 tailwinds of our 4-Star rating and increasing impact of our integrated care model, positions Clover for long-term Medicare Advantage success. We’re excited to keep pushing forward.”

News*

New out https://x.com/cloverhealth/status/1878804423834796334?s=46&t=0oBkpEBdmVv-_NnE0jX_yQ

Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization
WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”).

Based in Durham, North Carolina, DCC is a physician-led accountable care organization and integral component of one of the nation’s top academic medical centers, Duke University Health System, known for its groundbreaking research, world-class medical education, and exceptional patient care. As a premier provider of healthcare services, DCC encompasses a broad network of physicians and facilities focused on value-based healthcare.

Following a successful implementation, primary care physicians across DCC’s network of non-employed physicians now have access to Counterpart Health's technology to enable advanced decision support at the point of care. Leveraging Counterpart Assistant, a cloud-based AI platform designed to seamlessly integrate with existing electronic health record (EHR) systems, clinicians receive real-time, actionable insights to help improve chronic disease management and enhance patient outcomes while maintaining their established workflows.

“DCC supports Duke Health’s strategies of delivering exceptional health outcomes and cost- effective health care in a way that fully engages patients and their loved ones with dignity and compassion,” said John Yeatts, MD, MPH, and Executive Director of DCC. “One of our goals is to unify and optimize performance across our disparate network of non-employed community practices. By leveraging cutting-edge AI technology, we are empowering our physicians with actionable insights and driving improved health outcomes.”

Conrad Wai, CEO of Counterpart Health, added, “Duke Connected Care’s reputation as a global leader in academic medicine and healthcare innovation makes this partnership especially meaningful. Our technology is purpose-built to support clinicians by delivering personalized, data-driven insights, and we’re excited to see the transformative impact it is already having across Duke’s broad and diverse network of clinicians.”

Dr. Francis Aniekwensi, a Henderson, NC-based family physician who participates in DCC’s Accountable Care Organization (ACO) stated, "I think you guys are doing a great job reducing the burden on PCPs. Especially bringing data we don't have as a small rural practice. We can't afford a fancy EHR where we might be able to get some of that automatically. The better data we have, the better job we can do of taking care of our patients.”

For more information about Counterpart Health’s AI-powered solutions and their role in transforming healthcare delivery, visit www.counterparthealth.com.

The Christophers Show, he made a boo boo when he said "switching to us.... Clover Health Care".

Obviously, a paid promotion. But interesting nonetheless. Good stuff.

A must listen to video on Clover/Counterpart Health!

Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Remote-First Company -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time.

A live webcast and replay of the presentation and Q&A session will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.

It's time for Clover/Counterpart Health-Assistant to blow this up and get our AI Counterpart out there. We are the good guys, and the country is about to learn the truth about Clover Health!

'Wanted' Posters Targeting Healthcare Executives Mysteriously Pop Up in NYC: 'Wall Street CEOs Should Not Feel Safe'

So far, $CLOV has remained under the radar. That will not last very long though in my opinion.

Companies like $CLOV and $ELTP remain under the radar for most investors who follow the larger names.

Balance sheet for $CLOV is getting better and better. Same for the other.

Nice time to average down if only I had the money.

Clover Health CLOV the #1 Hidden Gem Stock in the USA? Top 77 Ranking EXPLAINED!

Buy while you can. Price is very inexpensive. Not financial advice, just my opinion.

$CLOV

Watch this incredible video on CLOV! Big things coming.

www.youtube.com/live/KkBsOO4lLvk

Dr Larry Nassar may be tapped by DJT for some sort of appointment to help Dr Oz with bad medical advice.

And Larry needs a break from jail too. He did nothing wrong.

😅😹😸🤣😂

Demetrious Kouzoukas appointed to the board of Clover Health in April 2021. Good friends with and appointed by DJT in 2017 as the Director of the CMS-Medicare until 2021. Bought 500K shares of CLOV January 2024 as reported on a FORM 4. Joined Medicare healthcare task force in April 2024. Will work directly with Dr. OZ and DJT regularly. Continues his BOD position with Clover/Counterpart Health on the BOD as shareholders ride the company into the future!

They will have a tough time holding this down IMO. $250K in legal fees is nothing. It's a sneeze.

There was the opportunity to drop the share price, and they took advantage of it. How long can they hold $CLOV down~?

My guess........... not very long. Too much happening in the market. No liquidity for shorts. It's all coming down on them.

Just my opinion. How much longer~? IMO, not very much longer at all.
Many tickers...........

Yeah, get ready......... IMO/

The shorts knew about this before the 10/25 8K filing hence another reason for that drop.
Clover Health Settles Legal Fees for $250,000 in Bylaw Suit
https://www.investing.com/news/company-news/clover-health-settles-legal-fees-for-250000-in-bylaw-suit-93CH-3684216

Holding pattern for many tickers. Temporary IMO.

Clover Health to Report Third Quarter 2024 Financial Results on November 6
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health’s third quarter 2024 business and financial results.

Third Quarter 2024 Conference Call and Webcast Details:

What: Clover Health’s Third Quarter 2024 Earnings Conference Call
When: Wednesday, November 6, 2024, at 5:00 p.m. Eastern Time
Dial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ324
Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of Clover Health’s website at https://investors.cloverhealth.com/ for 12 months

Seems many tickers are being pushed down right now. Just hang in there.
"They" cannot continue to keep doing this.
"They" are playing with fire.

Consider today to be a buying opportunity for many tickers out there.

$CLOV baby~!

Cramer's quote to a caller about CLOV from Tuesday last week.
When a caller inquired about Clover Health Investments, Corp. (NASDAQ:CLOV), Cramer said:

“Oh, man… I just don’t want to go there. I know that it’s a good company, but I just don’t want to hurt anybody. I’m sorry.”

Guarantee he is friends with the shorts!!!!!
CLOV began its drop from 4;70 to where we are today after that call was over
👿

Cramer's an ex-hedge fund manager like Dave McCormick. Cramer just looking out for his buddies and the 1%ers.
All the business channels doing the same thing. Many people like Charles Payne FOX, not me. He's the good cop while the others play bad cop.

If $CLOV isn't a flat out buy, what ticker is~? If I had the ching I would have bought more at $0.70/share. Pretty clear they are suppressing this like they do many tickers they bet against. People thought naked shorting was fiction~? "They" have done it for years and now they are EXPOSED to retail investors who they stole from for decades. The crime has all become so elaborate that the SEC, FINRA, and the DTCC know they themselves are exposed.

The whole market is screwed with just $GME and $AMC should they MOASS.

All my opinion. Not financial advice. Do your own due diligence.

When Cramer said that he wouldn't recommend CLOV because he didn't want to hurt anyone,he meant the shorts! That IMHO is a fact. BASTART he is!
I agree with you, were gonna have to wait for things to settle down.

All I will say is this........ "they" go after Keith Gill for posting MEMEs and accuse him of stock manipulation.
Cramer, who has his Mad Money Show gives advice on buys and sells all the time, however, he gets a break because his "show" is considered entertainment.

Yes, he and all his comrades are in lockstep with one another. Does not matter who or on what business channel. It's all connected to the 1% who must make their money. Retail investors, institutions, and pension funds who play by the rules get screwed. IMNSHO

They cannot keep $CLOV down IMO. I still maintain that $CLOV is heavily manipulated. "They" know what the deal is. Do not let them steal your shares~!

HODL

After what Jim Cramer said last week about CLOV only proves you're 100% correct. Notice how the stock sold off after hitting $4.70? Amazing that phone call was a setup!!! Manipulative fraudulent move but crooks are everywhere

BUYING OPP!

This is more than HUGE! Clover Health plans scored #1 AND #2 on a list of 508 Plans. Super, super exciting news that Clover’s 4.94 HEDIS clinical quality score in the Stars measure for 2023 measurement year ranked #1 amongst all Medicare Advantage all (PPO plans) nationally on the core HEDIS measures. Watch out shorts. The party starts next week. Q3 earnings and big guidance in just 2 weeks! GLTA LONGS!

This just came up, posted by Andrew Toy last night.

Clover is the top performing MA Plan in America on HEDIS Clinical Measures. Clover HEDIS measures for plans with over 2000 members performed the best, demonstrating the power of our approach!

Huge news is coming in the Q3 in just 2 weeks

Load up on "Call" options that expire 1 year out, and I think you will do very well. That's my strategy.

$CLOV bounced off a 52-week high of 4.71 today!

New Counterpart CMO talks Clover Health's AI capabilities:https://www.fiercehealthcare.com/payers/new-counterpart-cmo-talks-clover-healths-ai-capabilities

$CLOV hit $4.50 another 52-week high

2025 Clover Health Medicare Advantage Benefits Demonstrate Commitment to New Jersey Seniors
Company’s affordable, benefit-rich flagship PPO plans now have 4 Star rating
FRANKLIN, Tenn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Clover Health (Nasdaq: CLOV) (“Clover” or “the Company”) has announced the debut of its 2025 Medicare Advantage (MA) plan offerings in New Jersey. Clover offers a range of affordable and flexible healthcare options for Medicare beneficiaries, which are designed to meet the unique needs of New Jersey seniors, especially those on fixed incomes facing rising costs of living.

For full plan details, availability, and eligibility visit https://www.cloverhealth.com/plans.

“We are proud to reaffirm our commitment to New Jersey by maintaining our affordable benefit-rich PPO plans for 2025,” said Jamie Reynoso, Clover’s CEO of Medicare Advantage. “At a time when many plans are scaling back, Clover is the calm in the eye of the storm, delivering stability and increased value for our members.”

Clover’s 2025 plans in New Jersey focus on PPOs, but also include HMO offerings to cater to a wide range of healthcare needs. PPO plans offer highly competitive in-network and out-of-network costs, empowering members to access the care they need without the burden of high out-of-pocket expenses. For 2025, Clover has strengthened its product positioning to minimize disruption while delivering added value to members including low specialist and prescription drug copays, enhanced OTC and dental allowances, and a rewards program with the potential to earn up to $400 annually for completing healthy activities.

“After a decade of serving New Jersey’s Medicare beneficiaries, we understand the unique struggles they face, and we are committed to providing plans that deliver premium value as well as help them manage their day-to-day healthcare costs,” added Reynoso. “From offering the $400 rewards program to ensuring access to low-cost prescriptions and primary care, we’re here to help our members stay healthy without compromising on quality or affordability.”

Clover’s 2025 PPO plans received a 4 Star rating from the Centers for Medicare and Medicaid Services (“CMS”). Currently, over 95% of Clover’s Medicare Advantage membership is served through its PPO plans.

For information on Clover Health’s Medicare Advantage plans, visit www.cloverhealth.com.

Federal Contracting Disclaimer: Clover Health is a Preferred Provider Organization (PPO) and a Health Maintenance Organization (HMO) with a Medicare contract. Enrollment in Clover Health depends on contract renewal.

Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025
Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience
FRANKLIN, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare and Medicaid Services (“CMS”) has increased the Star rating of its PPO Medicare Advantage (“MA”) plans to 4 Stars for 2025, which will affect payment year 2026. Additionally, CMS increased the rating of Clover’s HMO MA plan to 3.5 Stars. Currently, over 95% of Clover’s Medicare Advantage membership is served through its PPO plans.

Each year CMS rates every plan on its healthcare quality and drug plan, and issues a Star rating on a scale of 1 to 5 Stars. For this measurement year, Clover’s overall Star rating was driven by the Company’s exceptional performance across a number of measures including Medication Adherence, the Healthcare Effectiveness Data and Information Set (“HEDIS”), and Consumer Assessment of Healthcare Providers and Systems (“CAHPS”). Clover earned an impressive 4.94 out of 5 Stars on HEDIS in particular, which is a set of performance measures quantifying a plan’s ability to deliver preventative screenings and comprehensively manage a range of health issues including diabetes, cancer, and heart disease.

"At Clover Health, our mission is centered around improving healthcare outcomes for our members, and our 4-Star CMS rating reaffirms our commitment to this goal,” said Andrew Toy, CEO of Clover Health. “Our investment in quality far exceeds industry standards, as demonstrated by our exceptional HEDIS score. By leveraging the power of Clover Assistant technology, we’re empowering physicians with real-time insights that directly enhance the quality of care through better preventive services and care coordination. We will continue prioritizing these efforts to drive impactful, long-term health improvements for our members."

"What we’ve been able to accomplish with this year’s Star ratings is a manifestation of the foundational improvements we’ve built over the last several years," said Jamie Reynoso, CEO of Medicare Advantage, Clover Health. "With a higher Star rating, we are able to further reinvest in more competitive benefits, which we believe will deliver greater value to our members while fueling continued membership growth. This milestone allows us to scale our impact to more people on Medicare without compromising our financial strength or commitment to care quality.”

To learn more about Clover Health and its Medicare Advantage plans visit www.cloverhealth.com. For providers, health systems and plans interested in learning about how they can use Clover’s proprietary technology stack to succeed in value based care, visit www.counterparthealth.com.

Federal Contracting Disclaimer: Clover Health is a Preferred Provider Organization (PPO) and a Health Maintenance Organization (HMO) with a Medicare contract. Enrollment in Clover Health depends on contract renewal.

Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart’s clinical strategy and product roadmap for Counterpart Assistant, the company’s proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).

David Tsay is a distinguished physician executive with deep expertise and over two decades of experience in health technology, product development, and clinical innovation. Prior to Counterpart, Dr. Tsay served in clinical leadership roles in the technology industry, most recently as Chief Medical Officer at Cue Health where he led regulatory, clinical, and medical affairs. Before Cue Health, Dr. Tsay led the clinical team for digital health medical device products at Apple. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation's most comprehensive academic healthcare delivery systems, leading digital transformation initiatives for NYP in artificial intelligence, automation, and digital web/mobile technologies.

Dr. Tsay received his BA in Computer Science and Physics from Columbia University College, M.D., Ph.D degrees from Columbia University College of Physicians and Surgeons, and is board certified in internal medicine and cardiology.

"Counterpart Health is built on groundbreaking technology that empowers physicians to excel in value-based care, particularly in the management of chronic diseases," said Conrad Wai, CEO of Counterpart Health. "Dr. Tsay’s world-class expertise in clinical innovation and health technology makes him a valuable addition to our team. I’m confident that his leadership will be instrumental as we accelerate our expansion into more value-based healthcare networks and systems nationwide."

"I’ve had the privilege of contributing to world-class institutions like Apple and NewYork-Presbyterian, which operate at the critical crossroads of healthcare and technology. Counterpart attracted me because it offers one of the most compelling solutions I’ve encountered," Tsay remarked. "With an increasing number of providers looking to deliver value-based care, Counterpart Assistant provides an innovative technology designed specifically for this purpose. I look forward to working alongside this skilled team in its mission to help improve providers’ and patients’ lives."

For companies interested in learning more about how Counterpart can reduce the total cost of care in value-based care models through advanced chronic disease management, visit www.counterparthealth.com.

About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Press Contact:
Andrew Still-Baxter
press@cloverhealth.com

Investor Relations Contact:

Just my opinion.......... they never covered their naked short positions when they scalped this years ago. I think they thought it would
go under as a business, or maybe they were hoping.

This ticker like many others in holding mode. 100% agree. Something big may be coming. A nice gamma squeeze~? or something even better~?

Patience is my mantra.

CLOV YTD

CLOV......................................https://stockcharts.com/h-sc/ui?s=CLOV&p=W&b=5&g=0&id=p86431144783

You gotta be as happy as a pig in shit PennyWorld. I'm happy to hear you're making $$$$$$ from ass-wipe short coverings 😁.

My "Call" options on this are doing very well too (up 46%). Most likely the short covering giving them a major lift.

Short Squeeze on the way. Check it out = Clover Health Investments's CLOV short percent of float has risen 28.4% since its last report. The company recently reported that it has 25.80 million shares sold short, which is 6.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.29 days to cover their short positions on average.

Good morning! Pre Market 52 week highs 🤩

🥰🥰🥰

The reason I think most people hate short sellers is because they prey on people and companies to fail. Pure evil. Longs prey that a company succeeds, and everyone makes money. If you hope for someone or thing to fail….your inherently evil and in it for only yourself. Now if you're shorting a medical company trying to save lives and preying on it to fail….god help you

CLOV......................https://stockcharts.com/h-sc/ui?s=CLOV&p=W&b=5&g=0&id=p86431144783

$4.00 breached! A new 52-week high!🥰

The shorties sems to come up with all sorts of delay tactics. Lawsuits, investigations, and other nonsense designed to
keep the Stock in check if not totally dismantle it altogether.

You understand 100%. Told a friend of mine about this stock when it was $0.70. Oh well. Can lead a horse to water.......... cannot make that horse drink.

My positions are tiny, but I'm still very optimistic, more so now than ever.

The day of reckoning is coming for "them". Am 100% sure of it. Rebuild the middle class.

$CLOV baby~!

It's very unfortunate but this shit goes on and on. 2 days ago they filed the 8k and it did nothing but now that the media picked up on it were soaring! These Maggott POS scum bag shorters made a fortune on this stock during the past 4 years and now they are covering as they lost their investigation. Any serious New contacts we soar past $5 FAST!
Thanks for keeping the faith as the majority didn't🥰

Maybe the SEC should investigate TRADE SWAPS designed to suppress the share price of MANY tickers.

Who are the MMs suppressing this ticker. The usual suspects~? CDEL and Virtu~?

Just saying...............

They will not investigate their own, the 1%ers......... Instead they protect them, while they do not protect retail investors, institutions, and pensions that follow the rules. All in my OPINION~!

CLOV still naked shorted......... anyone who denies that is a liar. Again MY OPINION~!
They scalped this ticker 3 years ago and left it for dead, or hoping it would die. It did not die as they had hoped.
Also my opinion.

$CLOV baby~!

From last night's 8K. = By letter dated September 26, 2024 (the “Notice”), the Staff of the Securities and Exchange Commission's (the "SEC") Division of Enforcement notified Clover Health Investments, Corp. (the “Company”) that the SEC had concluded its investigation of the Company commenced in February 2021 (the "Investigation"), and based on the information that the SEC had as of the date of the Notice, the Staff did not intend to recommend an enforcement action by the SEC against the Company relating to the Investigation. The Notice was provided under the guidelines set forth in the final paragraph of Securities Act Release No. 5310.

The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. Additional information regarding the Investigation can be found in the Company’s prior filings, including the Company’s Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 8, 2024.

CLOV 10 day hourly